Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for the treatment of type 2 diabetes mellitus (under the brand names Ozempic and Rybelsus) and chronic weight management (Wegovy)
Tirzepatide is injected subcutaneously once weekly, and the most common side effects include nausea, vomiting, diarrhea, headache, and injection site reactions
We help you manage them effectively.
Since its inception more than 50 years ago, BrightFocus and its flagship research programsAlzheimers Disease Research, Macular Degeneration Research, and National Glaucoma Researchhas awarded more than $330 million in research grants to scientists around the world, catalyzing thousands of scientific breakthroughs, life-enhancing treatments, and diagnostic tools
4 However, this research is preliminary, and semaglutide isnt licensed for migraine treatment